ZNF365 promotes stability of fragile sites and telomeres

Cancer Discovery

Volumn 3, Issue 7, 2013, Pages 798-811

  Zhang, Yuqing ^a   Shin, Sandra J ^a   Liu, Debra ^a   Ivanova, Elena ^c   Foerster, Friedrich ^c   Ying, Haoqiang ^d   Zheng, Hongwu ^b   Xiao, Yonghong ^c   Chen, Zhengming ^a   Protopopov, Alexei ^d   DePinho, Ronald A ^d   Paik, Ji Hye ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Simons Center for Quantitative Biology   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TRANSCRIPTOME; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ZNF365 PROTEIN;

ANEUPLOIDY; ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER RISK; CELLULAR DISTRIBUTION; CHROMOSOME ABERRATION; CHROMOSOME FRAGILE SITE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; TELOMERE; TELOMERE HOMEOSTASIS;

CELL AGING; CHROMOSOME ABERRATIONS; CHROMOSOME FRAGILE SITES; DNA DAMAGE; DNA-BINDING PROTEINS; GENOMIC INSTABILITY; HUMANS; NEOPLASMS; TELOMERE; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84880276680     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0536     Document Type: Article

References (49)

1. De Lange T. Telomere-related genome instability in cancer. Cold Spring Harb Symp Quant Biol 2005; 70: 197-204.
2. Palm W, de Lange T. How shelterin protects mammalian telomeres. Annu Rev Genet 2008; 42: 301-34.
3. Ye J, Lenain C, Bauwens S, Rizzo A, Saint-Leger A, Poulet A, et al. TRF2 and apollo cooperate with topoisomerase 2alpha to protect human telomeres from replicative damage. Cell 2010; 142: 230-42.
4. Sfeir A, Kosiyatrakul ST, Hockemeyer D, MacRae SL, Karlseder J, Schildkraut CL, et al. Mammalian telomeres resemble fragile sites and require TRF1 for efficient replication. Cell 2009; 138: 90-103.
5. Opresko PL, Mason PA, Podell ER, Lei M, Hickson ID, Cech TR, et al. POT1 stimulates RecQ helicases WRN and BLM to unwind telomeric DNA substrates. J Biol Chem 2005; 280: 32069-80.
6. Barefield C, Karlseder J. The BLM helicase contributes to telomere maintenance through processing of late-replicating intermediate structures. Nucleic Acids Res 2012; 40: 7358-67.
7. Chan KL, Palmai-Pallag T, Ying S, Hickson ID. Replication stress induces sister-chromatid bridging at fragile site loci in mitosis. Nat Cell Biol 2009; 11: 753-60.
8. Williams ES, Klingler R, Ponnaiya B, Hardt T, Schrock E, Lees-Miller SP, et al. Telomere dysfunction and DNA-PKcs deficiency: characterization and consequence. Cancer Res 2009; 69: 2100-7.
9. Celli GB, Denchi EL, de Lange T. Ku70 stimulates fusion of dysfunctional telomeres yet protects chromosome ends from homologous recombination. Nat Cell Biol 2006; 8: 885-90.
10. Wong KK, Maser RS, Bachoo RM, Menon J, Carrasco DR, Gu Y, et al. Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing. Nature 2003; 421: 643-8.
11. Maser RS, Wong KK, Sahin E, Xia H, Naylor M, Hedberg HM, et al. DNA-dependent protein kinase catalytic subunit is not required for dysfunctional telomere fusion and checkpoint response in the telomerase-deficient mouse. Mol Cell Biol 2007; 27: 2253-65.
12. Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T. p53-and ATMdependent apoptosis induced by telomeres lacking TRF2. Science 1999; 283: 1321-5.
13. Chin L, Artandi SE, Shen Q, Tam A, Lee SL, Gottlieb GJ, et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999; 97: 527-38.
14. Artandi SE, Chang S, Lee SL, Alson S, Gottlieb GJ, Chin L, et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000; 406: 641-5.
15. Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis 2010; 31: 9-18.
16. Davoli T, Denchi EL, de Lange T. Persistent telomere damage induces bypass of mitosis and tetraploidy. Cell 2010; 141: 81-93.
17. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010; 11: 220-8.
18. Myung K, Datta A, Kolodner RD. Suppression of spontaneous chromosomal rearrangements by S phase checkpoint functions in Saccharomyces cerevisiae. Cell 2001; 104: 397-408.
19. Arlt MF, Casper AM, Glover TW. Common fragile sites. Cytogenet Genome Res 2003; 100: 92-100.
20. Gaudet MM, Kirchhoff T, Green T, Vijai J, Korn JM, Guiducci C, et al. Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet 2010; 6: e1001183.
21. Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, et al. Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res 2012; 14: R33.
22. Christophorou MA, Martin-Zanca D, Soucek L, Lawlor ER, Brown-Swigart L, Verschuren EW, et al. Temporal dissection of p53 function in vitro and in vivo. Nat Genet 2005; 37: 718-26.
23. Chin K, de Solorzano CO, Knowles D, Jones A, Chou W, Rodriguez EG, et al. In situ analyses of genome instability in breast cancer. Nat Genet 2004; 36: 984-8.
24. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4: 814-9.
25. Wu L, Multani AS, He H, Cosme-Blanco W, Deng Y, Deng JM, et al. Pot1 deficiency initiates DNA damage checkpoint activation and aberrant homologous recombination at telomeres. Cell 2006; 126: 49-62.
26. Hockemeyer D, Daniels JP, Takai H, de Lange T. Recent expansion of the telomeric complex in rodents: Two distinct POT1 proteins protect mouse telomeres. Cell 2006; 126: 63-77.
27. Espejel S, Franco S, Sgura A, Gae D, Bailey SM, Taccioli G E, et al. Functional interaction between DNA-PKcs and telomerase in telomere length maintenance. EMBO J 2002; 21: 6275-87.
28. Chan SW, Blackburn EH. Telomerase and ATM/Tel1p protect telomeres from nonhomologous end joining. Mol Cell 2003; 11: 1379-87.
29. Henderson S, Allsopp R, Spector D, Wang SS, Harley C. In situ analysis of changes in telomere size during replicative aging and cell transformation. J Cell Biol 1996; 134: 1-12.
30. Garcia-Higuera I, Taniguchi T, Ganesan S, Meyn MS, Timmers C, Hejna J, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell 2001; 7: 249-62.
31. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003; 3: 23-34.
32. Chan KL, Hickson ID. On the origins of ultra-fine anaphase bridges. Cell Cycle 2009; 8: 3065-6.
33. Vinciguerra P, Godinho SA, Parmar K, Pellman D, D'Andrea AD. Cytokinesis failure occurs in Fanconi anemia pathway-deficient murine and human bone marrow hematopoietic cells. J Clin Invest 2010; 120: 3834-42.
34. Cesare AJ, Reddel RR. Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet 2010; 11: 319-30.
35. Hu J, Hwang SS, Liesa M, Gan B, Sahin E, Jaskelioff M, et al. Antitelomerase therapy provokes ALT and mitochondrial adaptive mechanisms in cancer. Cell 2012; 148: 651-63.
36. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J 1995; 14: 4240-8.
37. Perrem K, Colgin LM, Neumann AA, Yeager TR, Reddel RR. Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells. Mol Cell Biol 2001; 21: 3862-75.
38. Londono-Vallejo JA, Der-Sarkissian H, Cazes L, Bacchetti S, Reddel RR. Alternative lengthening of telomeres is characterized by high rates of telomeric exchange. Cancer Res 2004; 64: 2324-7.
39. Dunham MA, Neumann AA, Fasching CL, Reddel RR. Telomere maintenance by recombination in human cells. Nat Genet 2000; 26: 447-50.
40. Yeager TR, Neumann AA, Englezou A, Huschtscha LI, Noble JR, Reddel RR. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 1999; 59: 4175-9.
41. Jiang WQ, Zhong ZH, Henson JD, Reddel RR. Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference. Oncogene 2007; 26: 4635-47.
42. Cerone MA, Autexier C, Londono-Vallejo JA, Bacchetti S. A human cell line that maintains telomeres in the absence of telomerase and of key markers of ALT. Oncogene 2005; 24: 7893-901.
43. Celli GB, de Lange T. DNA processing is not required for ATMmediated telomere damage response after TRF2 deletion. Nat Cell Biol 2005; 7: 712-8.
44. Glover TW, Stein CK. Induction of sister chromatid exchanges at common fragile sites. Am J Hum Genet 1987; 41: 882-90.
45. Bosco N, de Lange T. A TRF1-controlled common fragile site containing interstitial telomeric sequences. Chromosoma 2012; 121: 465-74.
46. Wang Q, Du X, Meinkoth J, Hirohashi Y, Zhang H, Liu Q, et al. Characterization of Su48, a centrosome protein essential for cell division. Proc Natl Acad Sci U S A 2006; 103: 6512-7.
47. Lindstrom S, Vachon CM, Li J, Varghese J, Thompson D, Warren R, et al. Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. Nat Genet 2011; 43: 185-7.
48. Bacus S, Flowers JL, Press MF, Bacus JW, McCarty KS Jr. The evaluation of estrogen receptor in primary breast carcinoma by computerassisted image analysis. Am J Clin Pathol 1988; 90: 233-9.
49. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010; 123: 725-31.